Navigation Links
Genmab Announces 2008 First Half Year Results
Date:8/27/2008

Summary: Genmab Reports Results for the Six Month Period Ended June 30,

2008

COPENHAGEN, August 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the six month period ended June 30, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 277 million (USD 59 million) for the first half of 2008. In the same period of 2007, Genmab recognized revenues of DKK 280 million (USD 59 million).

An operating loss of DKK 471 million (USD 100 million). This compares to an operating loss of DKK 119 million (USD 25 million) reported for the corresponding period of 2007. The larger operating loss was driven by the increased level of pre-clinical and clinical activities associated with the advancement of our product pipeline.

Net financial income for the first half of 2008 reflected a net loss of DKK 20 million (USD 4 million), compared to a net income of DKK 32 million (USD 7 million) in the same period of 2007. The net financial income reflects a combination of interest income and fair market value adjustments from our portfolios of marketable securities and unrealized foreign exchange losses derived from the continued weakening of the USD against the DKK in the first half of 2008.

A net loss of DKK 491 million (USD 104 million) compared to a net loss of DKK 87 million (USD 18 million) for the same period in 2007. The net loss per share was DKK 11.02 (USD 2.33) for the first half of 2008 compared to DKK 2.01 (USD 0.42) in the first half of 2007.

Genmab ended the six month period with cash and marketable securities of DKK 2.1 billion (USD 443 million), which is a decrease of DKK 1.6 billion (USD 338 million) from the end of 2007. The decrease primarily arises from the DKK 1.2 billion (USD 240 million at the date of acquisition) acquisition of the manufacturing facility in March 2008.

Highlights

During the second quarter o
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
2. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... to a new market research report “Internet of Things ... Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building Automation, Consumer, ... - Global Trends & Forecasts to 2014 - 2020”, ... $1029.5 Billion in 2013, and is expected to reach ... 4.08% from 2014 to 2020. , Browse more ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 As reported ... and FiercePharma (Weintraub 7/11/14), a significant number of severe ... sugar, abdominal issues and even death from the highly-promoted ... According to the Times report , a regulatory ... 2013 reported by patients was almost 14% of prescriptions, ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 The ... the five years to 2014 on the heels of ... 2010 prompted farmers to dedicate a larger share of ... production. More specifically, the regulations required the mixing of ... expanding biofuel production in the United States created a ...
(Date:7/11/2014)... 2014 Ticket Down is a reliable source for ... View, CA. Over the years Luke Bryan has been honored ... does he do well at award shows, but each summer, he ... anticipated tours of the genre and this summer is more of ... compare to the popularity and success that is currently entitled to ...
(Date:7/11/2014)... July 11, 2014 Europe is one ... to large cultivated-and hence, irrigated land area. The agricultural ... Europe, accounting for around 30.0% of the total water ... greater in the southern region, but far from negligible ... irrigation accounts for over 60.0% of the water use ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... of blood tests over skin tests for detecting people ... effective, reliable and therefore holds promise in detecting latent ... dormant TB infection never actually get a full blown ... cases and offer treatment, which would take the pursuit ...
... a breach of trust if the court orders to release a ... and a patient.// The hospital said that it would do everything ... had an abortion at 32 weeks' pregnancy. She plans to take ... Appeal ordered that the woman's files be released to the Medical ...
... more number of bus drivers and conductors in India are ... of the bus conductor Ravindra Kamble (34). //Statistics show that ... year have been tested positive for HIV. The BEST’s HIV ... the previous year. ,He took the initiative for ...
... stem cell products through an IV line, in the years ... heart muscle in patients who have experienced heart attack for ... distinct advantage of the procedure is that intravenous infusion of ... a healthy donor can reverse heart tissue damage, elimininating the ...
... about increased risk of birth defects associated with letrozole, ... commonly given for infertility treatment has been settled//. A ... birth defects associated with letrozole is very similar to ... for infertility for more than 40 years that is ...
... that are associated with the menopause and dry eye is ... that the symptom is associated with the menopause or peri-menopause. ... risk of infection or visual impairment. ,The survey, sponsored ... percent of menopausal and peri-menopausal women reported that they experience ...
Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients 2Health News:Dry Eye Is A Symptom Of Menopause 2
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , REDWOOD CITY, Calif., ... its relationship and the signing of its second agreement this ... drug manufacturer. The new agreement covers three undisclosed pharmaceutical ... January 7. , Under the new agreement, Teva will use ...
... Md., Dec. 1 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases today announced that Bayer ... collaboration and license agreement entered into on January 12, 2009 ... solid tumors. , Under the terms of the agreement, Bayer ...
Cached Medicine Technology:Codexis Expands Collaboration with Teva 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: